A new study published in the Journal of Inflammation shows that the cystic fibrosis transmembrane conductance regulator (CFTR) plays an important role in regulating intestinal inflammatory responses.
Concert Pharmaceuticals has announced that it has initiated a clinical trial for its drug candidate CTP-656 for the treatment of cystic fibrosis.
OrPro Therapeutics, Inc, a cystic fibrosis treatment, has received a patent covering the drug’s capacity to improve the viscoelastic properties of mucus secretions.
Researchers have identified a genetic signature due to the inflammatory response in cystic fibrosis human bronchial epithelial cells infected with P. aeruginosa bacterium.
Researchers studying mucus in the lungs of cystic fibrosis (CF) patients has found that it may be a biomarker for progression of the disease.
Nivalis Therapeutics has announced positive data from its Phase 1b trial evaluating N91115 for cystic fibrosis.
RespirTech is now offering new vest patterns and custom decorative decals for its inCourage Airway Clearance System, used to treat cystic fibrosis, COPD, and bronchiectasis.
Aradigm has announced the completion of patient enrollment for ORBIT-4, a clinical trial of Pulmaquin for non-cystic fibrosis bronchiectasis.
With the Improving Access to Clinical Trials Act (IACT) of 2009 set to expire on October 5, 2015, the Cystic Fibrosis Foundation championed a new bill to make the IACT legislation permanent.
ProQR Therapeutics have begun enrolling patients in their exploratory trial for QR-010, a new therapy for cystic fibrosis.
Scientific experiments examining what happens to the faulty channel protein that causes cystic fibrosis (CF) during inflammation have yielded unexpected results.
Pulmatrix Inc will be presenting preclinical data on the pharmacokinetics and potency of PUR1900 during the upcoming 2015 North American Cystic Fibrosis Conference.
Mannitol has been found to be safe in cystic fibrosis patients and effective in improving the removal of respiratory secretions.
A team of researchers released recommendations against the use of Pseudomonas aeruginosa vaccines in patients with cystic fibrosis.
Scientists discover a small molecule that can substitute for a protein and restore a key cellular function related to the one missing in individuals with cystic fibrosis.
A study reveals that different bacterial populations in regions of the lungs of cystic fibrosis patients descend from the same bacterial strain, suggesting diverse bacteria exist in each region.
The Research Development Program of the Cystic Fibrosis Foundation has expanded its network and awarded grants to various research sites in the US.
A recent study found that P. aeruginosa status in cystic fibrosis patients can have an impact on their lung microbiota composition.
There are several therapeutic techniques for airway clearance. But with all the options, how does an RT decide which is the most effective for the patient?
A potential link may exist between metabolic fingerprints and the progression of cystic fibrosis, according to a new study.